Thrombocytopenia (13.0% with asciminib, 6.1% with imatinib, and 13.7% with second- generation TKIs), neutropenia (10.0%, 17.2%, and 17.6%), and leukopenia (2.0%, 10.1%, and 4.9%)
Hochhaus, Andreas, Jianxiang Wang, Dong-Wook Kim, et al. 2024. “Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.”New England Journal of Medicine 391 (10): 885–98. https://doi.org/10.1056/nejmoa2400858.